Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK statement regarding 2010 Nature Medicine study
GSK and Nature Medicine aware of allegations of misrepresentation of data in research paper written by scientists at GSK's China centre
-
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
GSK confirmed that FDA voted to continue to make Avandia (rosiglitazone) available to appropriate patients.
-
GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
GSK announced study of lapatinib with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint
-
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
GSK announced its Phase III trial of VOTRIENT met primary objective of a statistically significant improvement in PFS compared to placebo.
-
GSK strengthens vaccines business with acquisition of Okairos
GSK announced it's acquired Okairos, a specialist developer of vaccine platform technologies for €250 million (approx. £215/$325 million)
-
GSK and Genmab announce positive top-line results from pivotal trial of ARZERRA® (ofatumumab) combined with chlorambucil in previously untreated chronic lymphocytic leukaemia
GSK & Genmab announce phase III study of ARZERRA® with chlorambucil versus chlorambucil in patients with CLL met its primary endpoint.
-
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
GSK announced today that the FDA has approved both TAFINLAR® (dabrafenib) and MEKINIST™ (trametinib).
-
Grant to Help Coordinate Campaign to Train One Million Community Health Workers in sub-Saharan Africa
In an effort to expand health services in sub-Saharan Africa, GSK will donate $750,000 to One Million Community Health Workers Campaign.
-
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GSK & BARDA have agreed to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
-
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GSK & THRX announced that the FDA has approved BREO™ ELLIPTA™ as treatment in patients with COPD, including chronic bronchitis/emphysema.
-
GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries
GSK announced a commitment to GAVI Alliance to supply its cervical cancer vaccine to help protect girls in the world's poorest countries.
-
GSK and Save the Children form unique partnership to save the lives of one million children
A new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.
-
GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency
GSK today announced progress on its commitment to share more detailed data from its clinical trials.
-
Funding boost for GSK’s open innovation research into diseases affecting the developing world
GSK announced a funding of up to £5m from the Wellcome Trust to support discovering and developing new treatments for diseases
-
Regulatory update: Trametinib US PDUFA date extended to 3 September 2013
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib.
-
GSK announces regulatory submission for umeclidinium monotherapy in US
GSK announced the submission of a regulatory application in the US for umeclidinium bromide (UMEC), for patients COPD.
-
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
GSK & Impax announced that they are terminating their collaboration for the development of IPX066 outside the United States and Taiwan.
-
GSK announces regulatory submission for umeclidinium monotherapy in European Union
GSK announced the submission of a regulatory application to the EU for umeclidinium bromide (UMEC), for patients with COPD.
-
Results announcement for the first quarter 2013
GSK delivers Q1 2013 core EPS of 26.9p and dividend of 18p
-
GSK and Theravance announce regulatory submission for ANORO™ ELLIPTA™ (UMEC/VI) in Japan
GSK & THRX announced the submission of a regulatory application to the JMHLW for the LAMA/LABA medicine, UMEC/VI for patients COPD.
